# Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

> **NCT03003468** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lawrence Feldman, MD** · enrollment: 35 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Imprime PGG
- **DRUG:** MK-3475
- **DRUG:** Imprime PGG

## Key facts

- **NCT ID:** NCT03003468
- **Lead sponsor:** Lawrence Feldman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-11
- **Primary completion:** 2021-11-22
- **Final completion:** 2022-11-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003468, "Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03003468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*